Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Department of Molecular and Comparative Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Cancer Res. 2022 Oct 17;82(20):3802-3814. doi: 10.1158/0008-5472.CAN-21-4277.
HOXA5 is a transcription factor and tumor suppressor that promotes differentiation of breast epithelial cells and is frequently lost during malignant transformation. HOXA5 loss alone, however, does not confer tumorigenicity. To determine which molecular alterations combined with loss of HOXA5 expression can transform cells, we examined isogenic derivatives of a nonmalignant breast epithelial cell line containing knock-in or knockout mutations in key breast cancer genes. Knockdown (KD) of HOXA5 in cells harboring double knock-in (DKI) of mutated PIK3CA (E545K) and HER2 (V777L) induced epithelial-mesenchymal transition and migration and promoted invasive tumor outgrowth within mouse mammary ducts. The NF-κB pathway was significantly upregulated in DKI cells following HOXA5 KD. HOXA5 KD upregulated multiple NF-κB target genes, including IL6. IκBα protein, but not RNA, expression was reduced in HOXA5-KD cells. HOXA5 bound and stabilized IκBα, forming a nuclear HOXA5-IκBα complex. Chromatin immunoprecipitation sequencing database queries revealed that HOXA5 and IκBα are co-enriched at 528 genomic loci. In patients with breast cancer, high coexpression of HOXA5 and IκBα conferred a significantly better overall and progression-free survival. Collectively, these data suggest that HOXA5 suppresses malignancy in breast epithelial cells by blunting NF-κB action via stabilization of its inhibitor IκBα.
Loss of HOXA5 reduces IκBα stability and increases NF-κB signaling to exacerbate breast cancer aggressiveness, providing new insights into the tumor suppressor functions of HOXA5.
HOXA5 是一种转录因子和肿瘤抑制因子,可促进乳腺上皮细胞的分化,并且在恶性转化过程中经常丢失。然而,单独丢失 HOXA5 并不能赋予肿瘤形成能力。为了确定哪些分子改变与 HOXA5 表达的丧失相结合可以转化细胞,我们检查了含有关键乳腺癌基因敲入或敲除突变的非恶性乳腺上皮细胞系的同基因衍生物。在携带突变 PIK3CA(E545K)和 HER2(V777L)的双敲入(DKI)细胞中敲低(KD)HOXA5 可诱导上皮-间充质转化和迁移,并促进小鼠乳腺导管内侵袭性肿瘤生长。NF-κB 途径在 DKI 细胞中 HOXA5 KD 后显著上调。HOXA5 KD 上调了多个 NF-κB 靶基因,包括 IL6。HOXA5-KD 细胞中 IκBα 蛋白的表达减少,但 RNA 表达没有减少。HOXA5 结合并稳定 IκBα,形成核 HOXA5-IκBα 复合物。染色质免疫沉淀测序数据库查询显示,HOXA5 和 IκBα 在 528 个基因组位点上共同富集。在乳腺癌患者中,HOXA5 和 IκBα 的高共表达可显著改善总生存和无进展生存。总之,这些数据表明,HOXA5 通过稳定其抑制剂 IκBα 来抑制 NF-κB 作用,从而抑制乳腺上皮细胞的恶性程度。
HOXA5 的丢失降低了 IκBα 的稳定性并增加了 NF-κB 信号,从而加剧了乳腺癌的侵袭性,为 HOXA5 的肿瘤抑制功能提供了新的见解。